As patients with chronic liver diseases and concurrent autoimmune rheumatic diseases or osteoarthritis have been excluded from our current and previous study [17], our findings suggest that COMP fragments could be detected in the serum samples of patients with liver diseases during the fibrogenic process, potentially representing the level of the fibrogenic activity in the liver. This evidence concerns the gene COMP and osteoarthritis.